Board Meeting14 Aug 2026, 05:23 pm
Norris Medicines Board Approves Q1 FY27 Un-Audited Results
AI Summary
Norris Medicines Limited held a Board Meeting on August 14, 2026, to approve the un-audited financial results for the quarter ended June 30, 2026 (Q1 FY27). The Board also approved the appointment of Mr. Vimal Dhirendra Shah as Managing Director for a three-year term, effective September 1, 2026, subject to shareholder approval. The financial results were reviewed by statutory auditors and will be published in newspapers.
Key Highlights
- Board approved un-audited financial results for Q1 FY27.
- Mr. Vimal Dhirendra Shah appointed as Managing Director.
- Appointment is for a 3-year term effective September 1, 2026.
- Appointment is subject to shareholder approval.
- Financial results to be published in newspapers.
Price Impact
More from NORRIS